Naldemedine (Nal) is widely used as a therapeutic drug against opioid-induced constipation. However, patients in phase III trials are limited to those with good performance status (PS). Cancer patients may have inferior PS owing to progression of symptoms and adverse events from chemotherapy. Therefore, it is important to survey the efficacy of Nal in patients with poor PS. This study aimed to evaluate Nal efficacy in patients with poor PS. We retrospectively investigated patients from July 2017 to June 2019 and compared Nal efficacy between patients with good and poor PS. The efficacy of Nal was evaluated using changes in the number of spontaneous bowel movements 7 days before and after the introduction of Nal with reference to previous reports. Multivariate analysis was performed to reveal whether poor PS aŠects Nal efficacy. In total, 141 patients at the Hokkaido University Hospital were analyzed. The eŠective rate of Nal from day 1 to day 7 of administration was 71.7％ and 71.4％ in the patients with good and poor PS, respectively, that from day 1 to day 2 of administration was 61.1％ and 57.1％, respectively, and that from day 3 to day 7 of administration was 60.2％ and 71.4％, respectively, suggesting an absence of significant diŠerences. Furthermore, results of multivariate analysis showed that ``best supportive care'' and ``body weight (55 kg and above)'' reduced Nal efficacy. In conclusion, Nal showed similar eŠectiveness in patients with poor PS as that in those with good PS.
ASJC Scopus subject areas